Neovascularisation in tendinopathy: from eradication to stabilisation?

Tero AH Järvinen

Tendinopathy is the most common disorder in sports medicine. Multiple hypotheses have been proposed for the aetiopathogenesis, but many aspects still remain elusive. Microdialysis studies have shown high levels of lactate within tendinosis, even at resting tendons, suggesting that hypoxia persists in tendinopathy. The presence of necrotic tenocytes, blocked arteries and anaerobic enzymes within tendinopathy lesions lend further support to the role of hypoxia in the aetiopathogenesis. Finally, ‘tendinosis’, the pathognomonic histopathological finding in tendinopathy, is composed of hypoxic, mucoid, hyaline and fibrinoid tissue. These tissue types are known to be hypoxia induced.

Tendons are generally poorly vascularised, while certain regions—those most prone to injury—are almost avascular. This can be considered an evolutionary ‘design failure’ that makes tendons susceptible to chronic and acute injuries. As a consequence, healthy tendons have a virtually non-existent tissue turnover throughout adulthood. However, somewhat paradoxically, tissue turnover is increased in tendinopathic tendons. Given the persisting hypoxia and subsequent anaerobic metabolism, it comes as no surprise that the enhanced tissue turnover leads to production of poorly organised tissue—tendinosis—in tendinopathy.

The fundamental survival mechanism of any cell under hypoxia is the activation of hypoxia-inducible factor-1α (HIF-1α), a transcription factor that turns on expression of a large range of genes encoding angiogenic growth factors. Characteristic features of both tendinopathic and ruptured tendons are elevated expression of HIF-1α and its target genes, the proangiogenic growth factors, such as vascular endothelial growth factor and abundant neovascularisation.

The neovascularisation has even been proposed as the origin of tendinopathy-related pain, and accordingly, its eradication has been used as a therapy for the condition. Given that tissue regeneration requires sufficient supply of oxygen and nutrients, the existence of neovascularisation in tendinopathy should be interpreted as a sign of both persisting hypoxia and failed tissue repair attempt.

Although almost completely ignored in sports medicine, it is well-established in the fields of cancer biology and retinopathy that hypoxia-induced neovessels are hyperpermeable. In essence, they leak and do not have proper perfusion (figure 1). These hyperpermeable neovessels fail to deliver oxygen and nutrients required for tissue maintenance and possible regeneration. Hyperpermeability also explains the apparent intellectual paradox as to why there is persisting hypoxia within regions of neovascularity.

As noted, there are some preliminary data to suggest that eradication of neovascularisation has some efficacy in the treatment of tendinopathy. However, from a biological perspective, it is somewhat counterintuitive to assume that eradication of neovessels—those originally induced by cells struggling to survive under hypoxic conditions—could offer a viable long-term solution for tendinopathy. At least, in cancer and retinopathy—conditions with similar vascular changes—angiogenic therapies have merely worsened the underlying ischaemia.

A tempting alternative approach is to ‘normalise’ or ‘stabilise’ the neovessels (figure 1). These ‘stabilised’ blood vessels with structurally intact vessel walls (lumenisation) and proper perfusion could replenish the supply of oxygen and nutrients and, consequently, enable proper tendon regeneration (figure 1). Although normalisation of neovascularisations may sound like science fiction, recent discoveries in vascular biology offer new hope, as genes responsible for the stabilisation of neovessels have been

Figure 1 Stabilisation of neovessels in tendinopathy. (A) Tendons respond to hypoxia by secreting angiogenic growth factors that induce the growth of neovessels in tendinopathy. (B) These neovessels are hyperpermeable; they leak and do not have proper perfusion, failing to deliver oxygen and nutrients required for tissue regeneration. Fibrin-rich exudates leak from the neovessels, which results in fibrinoid degeneration, a typical feature of tendinosis in tendinopathy. (C) Future therapies should aim to ‘stabilise’ the neovessels, re-establishing the structural integrity of the vessel walls (lumenisation) and consequently enabling proper perfusion that replenishes supply of oxygen and nutrients. Picture adapted with permission from Taylor and Francis Group.
Editorial

hypoxia-induced pathogenesis for tendinopathy might seem at odds with Doppler ultrasound studies that have shown normal oxygen saturation in tendinopathic tendons. However, arterio-venous anastomoses are common in diseased tendons, providing a bypass route for circulation and thus a plausible explanation for the failure to detect reduced oxygen saturation in tendinopathic tendons. In the end, hypoxia is the only possible explanation for the reported high levels of lactate and particularly for the characteristic histopathological findings in tendinopathic tendons.

The quest for new therapies in sports medicine should rely on the discoveries of basic science. The novel model presented proposes a pivotal role for hypoxia in the pathogenesis of tendinopathy. Tendons respond to hypoxia by secreting angiogenic growth factors to induce the growth of neovessels (figure 1). Unfortunately, these neovessels are non-functional by nature, failing to deliver oxygen and nutrients required to reverse the prevailing hypoxia. Stabilisation of neovessels could offer a tempting future therapeutic approach for the treatment of tendinopathy.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.


ORCID id

Tero AH Järvinen http://orcid.org/0000-0002-4027-1759

REFERENCES